GT Biopharma, Inc. quarterly report, Q3 FY2024 (NASDAQ:GTBP)

This Form 10-Q covers the quarterly period ended September 30, 2024. GT Biopharma, Inc. is a clinical-stage biopharmaceutical company developing immune-oncology products based on its proprietary Tri-specific Killer Engager (TriKE®) and Dual Targeting TriKE® platforms. The company has no approved products and generates no revenue. Effective July 1, 2024, the company became fully remote with no principal executive office.

Key Financial Metrics (Nine Months Ended Sept 30, 2024)

Revenue: $0 (No product sales).
Net Loss: $9.387 million (vs. $4.635 million in the prior year period).
Operating Expenses: $10.601 million total.
- Research and Development (R&D): $3.868 million.
- Selling, General, and Administrative (SG&A): $6.733 million.
Cash Flow:
- Net cash used in operating activities: $10.436 million.
- Net cash provided by investing activities: $12.892 million (primarily from sale of short-term investments).
- Net cash provided by financing activities: $2.976 million (proceeds from stock issuance).
Liquidity: Cash and cash equivalents totaled $6.418 million as of September 30, 2024 (up from $1.079 million at year-end 2023). Restricted cash was $93,000.
Debt: No interest-bearing debt reported; however, a warrant liability of $182,000 remains on the balance sheet.
Working Capital: $2.097 million (Current Assets $6.759M - Current Liabilities $4.662M).

Material Changes vs. Prior Period

Net Loss Increase: Net loss increased by approximately $4.75 million (103%) compared to the nine months ended September 30, 2023. This was primarily driven by a decrease in the non-cash gain from the change in fair value of warrant liability ($3.9 million reduction in gain) and increased legal/professional fees.
Expense Shifts: R&D expenses decreased by $1.24 million (24%) due to lower project material costs. SG&A expenses increased by $2.98 million (84%), largely due to legal fees and an accrual for a probable legal settlement.
Stock-Based Compensation: Stock-based compensation expense decreased significantly to $222,000 from $1.767 million in the prior year period.
Balance Sheet: Total assets decreased from $14.1 million to $6.8 million, primarily due to the liquidation of $12.9 million in short-term investments to fund operations.

Outlook, Risks, and Contingencies

Going Concern: The filing explicitly states that the company's financial condition raises substantial doubt about its ability to continue as a going concern for one year from the issuance date. Management believes existing cash resources are insufficient to fund anticipated operations without additional financing.
Product Pipeline:
- GTB-3650: Received FDA clearance for its IND application in June 2024. Enrollment for a Phase 1 trial in relapsed/refractory AML is anticipated in the second half of 2024.
- GTB-5550: Pre-IND packet submitted; IND filing anticipated in the first half of 2025 for solid tumors.
Legal Proceedings:
- Ohri Matter: Arbitration filed against former CFO Manu Ohri for breach of fiduciary duties; counterclaims filed by Ohri. Outcome uncertain.
- Berk Matter: Lawsuit by former interim CEO regarding whistleblower retaliation; parties agreed to resolve, dismissal expected.
- TWF Global Matter: Dispute regarding convertible notes and share registration; hearing set for November 14, 2024.
Related Party Commitments: Significant accounts payable to Cytovance Biologics, Inc. ($638,000) and the University of Minnesota ($697,000). Unbilled commitments to Cytovance total approximately $1.3 million.

Investor Verification Checklist

Cash Runway: Verify if the $6.4 million cash balance is sufficient to fund the upcoming GTB-3650 clinical trial enrollment and operations through the next 12 months given the "substantial doubt" disclosure.
Financing Plans: Confirm if the company has secured or is actively pursuing new equity financing to address the liquidity gap.
Legal Accruals: Review the specific amount accrued for the "probable settlement" of the legal matter mentioned in SG&A expenses.
Related Party Payables: Assess the risk of further dilution if the company settles the $1.3 million in unbilled commitments to Cytovance via stock issuance, as done previously.
Warrant Liability: Monitor the fair value of the remaining $182,000 warrant liability, as fluctuations in stock price will continue to impact net income/loss.